Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuPharma has commenced a dose escalating open label study of its cancer compund IPP-204106 in patients with at least one treatment failure according to standard regulatory guidelines.
Subscribe to our email newsletter
According to ImmuPharma, the study was designed to show safety and tolerability and assess the maximum tolerated dose of IPP-204106.
In the trial, the patients were dosed with an initial dose of 40mg/sq.m. or 1mg/kg and if stabilisation or improvement occurs, then patients continued treatment for an additional 4 sessions.
So far 6 patients have been dosed in the trial who are suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis.
ImmuPharma intends to file a US IND in the next few months and commence a Phase IIb programme in the first half of 2011in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.